Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications

Biological Psychiatry

Volumn 49, Issue 4, 2001, Pages 374-384

  Green, Michael F ^a   Braff, David L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Psychiatry ^*  (United States)

Author keywords

Animal models; Drug development; Neurocognition; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CLINICAL RESEARCH; COGNITIVE DEFECT; DRUG MECHANISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL PROBLEM; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BRAIN; CLINICAL TRIALS; COGNITION DISORDERS; HUMANS; SCHIZOPHRENIA;

EID: 0035865479     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)01027-1     Document Type: Review

References (77)

1. Defining the phenotype of schizophrenia: Cognitive dysmetria and its neural mechanisms
2. Residual performance deficit in clinically remitted schizophrenia: A marker of schizophrenia?
3. Span of apprehension performance, neuropsychological functioning, and indices of psychosis-proneness
4. An attentional assessment of foster children at risk for schizophrenia
5. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine
6. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response
7. Susceptibility to type A backward pattern masking among hypothetically psychosis-prone college students
8. Sensorimotor gating and habituation evoked by electro-cutaneous stimulation in schizophrenia
9. Impaired speed of information processing in nonmedicated schizotypal patients
10. Connecting the "dots" of brain dysfunction in schizophrenia: What does the picture look like?
11. Gating and habituation of the startle reflex in schizophrenia patients
12. Effect of antipsychotic medication on speed of information processing in schizophrenia patients
13. Prestimulus effects on human startle reflex in normals and schizophrenias
14. Neuroanatomy of schizophrenia
15. Schizophrenia and glutamate
16. Strong inferences, theory testing, and the neuroanatomy of schizophrenia
17. Neuroleptics: Effects on neuropsychological function in chronic schizophrenia patients
18. Global attentional deviance as a marker of risk for schizophrenia: Specificity and predictive validity
19. The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenia and depressed patients
20. Construct validity in psychological tests
21. Effects of D2 dopamine receptor antagonists on fos protein expression in the striatal complex and entorhinal cortex of the nonhuman primate
22. Postmortem studies of the hippocampal formation in schizophrenia
23. Continuous performance tests in schizophrenia patients: Stimulus and medication effects on performance
24. Neuroanatomical targets of neuroleptic drugs as revealed by fos immunochemistry
25. A PET study of word finding
26. Functional and anatomical aspects of prefrontal pathology in schizophrenia
27. The basal ganglia and cognitive pattern generators
28. What are the functional consequences of neurocognitive deficits in schizophrenia?
29. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff?"
30. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
31. Startle gating deficits occur across prepulse intensities in schizophrenia patients
32. Familial prevalence and coaggregation of schizotypy indicators: A multitrait family study
33. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenia patients receiving clozapine
34. Social-adaptive functioning evaluation (SAFE): A rating scale for geriatric psychiatric patients
35. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: A comparison across treatment sites
36. Introduction to the complex genetics of mental disorders
37. The NIMH perspective. Next steps in schizophrenia research
38. Cortical development and thalamic pathology in schizophrenia
39. Preliminary evidence of an association between sensorimotor gating and distractibility in psychosis
40. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: Preliminary findings
41. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia
42. Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia
43. Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients
44. Risperidone vs. haloperidol on secondary memory: Can newer medications aid learning?
45. Normalization of information processing deficits in schizophrenia with clozapine
46. Schizotypy and sustained attention
47. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine
48. Dopaminergic stimulation disrupts sensorimotor gating in the rat
49. The longitudinal relationship of clinical symptoms, cognitive functioning and adaptive life in geriatric schizophrenia
50. High school yearbooks: A reply to Schwartz
51. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values
52. The effect of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
53. Information processing deficits in remitted schizophrenias
54. On familial factors in the attentional deficit in schizophrenia: A review and report of two new subject samples
55. Signal detection in vigilance tasks and behavioral attributes among offspring of schizophrenia mothers and among hyperactive children
56. Developmental processes in schizophrenia disorders: Longitudinal studies of vulnerability and stress
57. The Brief Psychiatric Rating Scale
58. The nonlinear, complex sequential organization of behavior in schizophrenia patients: Neurocognitive strategies and clinical correlations
59. Information-processing deficits and thought disorder in schizophrenia
60. Working memory in schizophrenia: Transient "on-line" storage versus executive functioning
61. Thought disorder and psychosocial functioning in schizophrenia: The concurrent and predictive relationships
62. Effects of olanzapine on regional c-fos expression in rat forebrain
63. Sustained attention in children at risk for schizophrenia: Findings with two visual continuous performance tests in a new sample
64. An abbreviation of the WAIS for clinical use
65. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia
66. Electrophysiological and behavioral signs of attentional disturbance in schizophrenias and their siblings
67. Relationships between medication treatments and neuropsychological test performance in schizophrenia
68. GABAergic projection from nucleus accumbens to ventral pallidum mediates dopamine-induced sensorimotor gating deficits of acoustic startle in rats
69. Schizophrenic-like sensorimotor gating abnormalities in rats following dopamine infusion into the nucleus accumbens
70. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenia patients
71. Neural substrates of sensorimotor gating of the startle reflex: A review of recent findings and their implications
72. Dopamine, schizophrenia, mania, and depression: Toward a unified hypothesis of cortico-striato-pallido-thalamic function
73. The functional significance of symptomatology and cognitive function in schizophrenia
74. Effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients
75. Implications of normal brain development for the pathogenesis of schizophrenia